Robert Andrade Fennec Pharmaceuticals Inc. (FENC) insider trading activity

FENC Quotes by TradingView

Robert Andrade is CHIEF FINANCIAL OFFICER of FENNEC PHARMACEUTICALS INC.. Currently has a direct ownership of 201,100 shares of FENC, which is worth approximately $1.63 Million. The most recent transaction as insider was on Jan 15, 2026, when has been sold 10,000 shares (Common Shares) at a price of $2.45 per share, resulting in proceeds of $24,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 201K
17.83% 3M change
55.33% 12M change
Total Value Held $1.63 Million

Robert Andrade Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 15 2026
BUY
Exercise of conversion of derivative security
$24,500 $2.45 p/Share
10,000 Added 4.74%
201,100 Common Shares
Jan 07 2026
BUY
Exercise of conversion of derivative security
$34,750 $2.45 p/Share
14,184 Added 6.91%
191,100 Common Shares
Dec 31 2025
BUY
Grant, award, or other acquisition
-
1,382 Added 0.78%
176,916 Common Shares
Dec 01 2025
BUY
Grant, award, or other acquisition
-
2,430 Added 1.37%
175,534 Common Shares
Oct 31 2025
BUY
Grant, award, or other acquisition
-
2,430 Added 1.38%
173,104 Common Shares
Sep 30 2025
BUY
Grant, award, or other acquisition
-
2,430 Added 1.4%
170,674 Common Shares
Aug 31 2025
BUY
Grant, award, or other acquisition
-
2,431 Added 1.42%
168,244 Common Shares
Jul 31 2025
BUY
Grant, award, or other acquisition
-
2,431 Added 1.44%
165,813 Common Shares
Jun 30 2025
BUY
Grant, award, or other acquisition
-
2,431 Added 1.47%
163,382 Common Shares
May 31 2025
BUY
Grant, award, or other acquisition
-
2,431 Added 1.49%
160,951 Common Shares
May 22 2025
BUY
Exercise of conversion of derivative security
$41,922 $5.1 p/Share
8,220 Added 4.93%
158,520 Common Shares
May 16 2025
BUY
Grant, award, or other acquisition
-
16,667 Added 9.98%
150,300 Common Shares
Apr 30 2025
BUY
Grant, award, or other acquisition
-
1,042 Added 0.77%
133,633 Common Shares
Mar 31 2025
BUY
Grant, award, or other acquisition
-
1,042 Added 0.78%
132,591 Common Shares
Feb 28 2025
BUY
Grant, award, or other acquisition
-
1,042 Added 0.79%
131,549 Common Shares
Jan 31 2025
BUY
Grant, award, or other acquisition
-
1,042 Added 0.79%
130,507 Common Shares
Dec 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.8%
129,465 Common Shares
Dec 02 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.8%
128,423 Common Shares
Nov 18 2024
BUY
Exercise of conversion of derivative security
$38,749 $2.45 p/Share
15,816 Added 11.04%
127,381 Common Shares
Oct 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.93%
111,565 Common Shares
Sep 30 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.93%
110,523 Common Shares
Aug 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.94%
109,481 Common Shares
Jul 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.95%
108,439 Common Shares
Jul 01 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.96%
107,397 Common Shares
May 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.97%
106,355 Common Shares
RA

Robert Andrade

CHIEF FINANCIAL OFFICER
Research Triangle Park, NC

Track Institutional and Insider Activities on FENC

Follow FENNEC PHARMACEUTICALS INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FENC shares.

Notify only if

Insider Trading

Get notified when an Fennec Pharmaceuticals Inc. insider buys or sells FENC shares.

Notify only if

News

Receive news related to FENNEC PHARMACEUTICALS INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on FENC